- Home
- EXEL
EXEL
Exelixis Inc.
as 05-09-2025 4:00pm EST
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Upcoming Earnings Alert:
Get ready for potential market movements as Exelixis Inc. EXEL prepares to release earnings report on 13 May 2025.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 9.8B | IPO Year: | 2000 |
| Target Price: | $37.59 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.76 | EPS Growth: | 170.77 |
| 52 Week Low/High: | $20.14 - $40.26 | Next Earning Date: | 05-13-2025 |
| Revenue: | $2,168,701,000 | Revenue Growth: | 18.50% |
| Revenue Growth (this year): | 5.78% | Revenue Growth (next year): | 10.94% |
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aftab Dana | EXEL | CSO/EVP Disc & Trans Research | May 1 '25 | Sell | $39.00 | 1,508 | $58,812.00 | 693,181 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Mar 3 '25 | Sell | $38.80 | 10,000 | $388,000.00 | 341,028 | |
| WYSZOMIERSKI JACK L | EXEL | Director | Feb 28 '25 | Sell | $37.80 | 8,768 | $331,430.40 | 356,605 | |
| Smith Julie | EXEL | Director | Feb 27 '25 | Sell | $37.88 | 73,808 | $2,804,459.10 | 10,778 | |
| Oliver Bob | EXEL | Director | Feb 25 '25 | Sell | $37.25 | 18,647 | $694,600.75 | 33,514 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Feb 24 '25 | Sell | $36.98 | 52,636 | $1,946,479.28 | 341,028 | |
| Aftab Dana | EXEL | CSO/EVP Disc & Trans Research | Feb 24 '25 | Sell | $36.75 | 26,987 | $991,772.25 | 693,181 | |
| Senner Christopher J. | EXEL | EVP and CFO | Feb 24 '25 | Sell | $36.14 | 29,314 | $1,059,407.96 | 779,607 | |
| Beckerle Mary C | EXEL | Director | Feb 14 '25 | Sell | $34.89 | 12,210 | $425,878.38 | 30,406 | |
| Eckhardt Sue Gail | EXEL | Director | Feb 14 '25 | Sell | $35.03 | 11,568 | $405,111.36 | 34,262 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Business Wire
2 days ago
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Argus Research
3 days ago
EXEL: Lowering target price to $40.00
Insider Monkey
6 days ago
Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy
Zacks
7 days ago
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Business Wire
10 days ago
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Zacks
10 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Investor's Business Daily
13 days ago
MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
Compare EXEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.